- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Tarrytown Today
By the People, for the People
Jefferies Financial Group Acquires Regeneron Pharmaceuticals Shares
Institutional investor adds 25,535 shares of biotech company to portfolio
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
Jefferies Financial Group Inc. has acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), purchasing 25,535 shares of the biopharmaceutical company's stock during the third quarter, according to a recent SEC filing. The shares are valued at approximately $14,358,000.
Why it matters
Regeneron is a prominent biotech firm known for its innovative drug discovery technologies, including its VelocImmune platform for generating fully human monoclonal antibodies. This investment by Jefferies Financial Group, a major institutional investor, signals confidence in Regeneron's continued growth and product pipeline.
The details
According to the filing, Jefferies Financial Group acquired the 25,535 shares of Regeneron Pharmaceuticals during the third quarter. The purchase adds to a number of other hedge funds and institutional investors that have also modified their holdings of REGN stock in recent quarters, including Brighton Jones LLC, Dynamic Technology Lab Private Ltd, Wedbush Securities Inc., Penserra Capital Management LLC, and AE Wealth Management LLC.
- Jefferies Financial Group acquired the Regeneron shares during the third quarter of the year.
- The SEC filing disclosing the transaction was published on March 9, 2026.
The players
Jefferies Financial Group Inc.
A global investment banking firm and diversified financial services company.
Regeneron Pharmaceuticals, Inc.
A U.S. biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.
The takeaway
Jefferies Financial Group's investment in Regeneron Pharmaceuticals underscores the biotech firm's prominence in the industry and the confidence institutional investors have in its growth potential and innovative drug pipeline.
